Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
2,059 stopped studies mapped to Carcinoma of Unknown Primary and descendants · 91% state a reason
Over the 2,059 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT01628913 | Efficacy and Safety of BEZ235 Compared to Everolimus in Patients With Advanced Pancreatic… | Phase 2 | terminated | Jun 27, 2012 | Novartis Pharmaceuticals | This trial was terminated based on an interim analysis as BEZ235 did not demonstrate a progression… | Efficacy / futility |
| NCT01860742 | Randomized Phase III of PRRT Versus Interferon(CASTOR) | Phase 3 | withdrawn | May 23, 2013 | Jules Bordet Institute | not stated | Not stated |
| NCT02059252 | Safety, Tolerability and Performance of SmartMatrix Dermal Replacement Scaffold | Phase 1 / Phase 2 | terminated | Feb 11, 2014 | Smart Matrix Limited | Mode of application to be reconsidered by Sponsor | Other (stated, no rule matched) |
| NCT01285635 | A Study of AT-101 in Combination With Docetaxel in Squamous Cell Carcinoma Of The Head… | Phase 2 | terminated | Jan 28, 2011 | University of Michigan Rogel Cancer Center | drug is no longer manufactured | Drug supply |
| NCT00556205 | Bevacizumab With or Without Sunitinib in Sunitinib-Refractory Renal Cell Carcinoma | Phase 2 | withdrawn | Nov 9, 2007 | Massachusetts General Hospital | Toxicity of combination from other trials | Safety / toxicity |
| NCT01962909 | Phase 0 Biodistribution of Novel Imaging for Resectable Pancreatic Cancer | Early Phase 1 | terminated | Oct 14, 2013 | University of Virginia | From preliminary imaging data, the study was stopped due to futility. | Efficacy / futility |
| NCT00440973 | Safety Study of Specific Tumor Target Drug Plus Immune System Therapy in Patients With… | Phase 2 | terminated | Feb 27, 2007 | The Methodist Hospital Research Institute | contract issues | Other (stated, no rule matched) |
| NCT00522249 | Study of Pegylated Alfa Interferon, Sunitinib and Tarceva in Patients With Metastatic RCC | Phase 1 / Phase 2 | terminated | Aug 29, 2007 | The Methodist Hospital Research Institute | PI decision | Other (stated, no rule matched) |
| NCT02307474 | A Pilot Study of SBRT With Adjuvant Pazopanib for Renal Cell Cancer | N/A | withdrawn | Dec 4, 2014 | Case Comprehensive Cancer Center | Funding Unavailable | Funding |
| NCT01819428 | NOV120101 (Poziotinib) for 1st Line Monotherapy in Patients With Lung Adenocarcinoma | Phase 2 | terminated | Mar 27, 2013 | National OncoVenture | Low recruitment | Enrollment / accrual |
| NCT02014831 | Efficacy and Safety of Cetuximab in Metastatic Penile Carcinoma (PENILANE)(PENILANE) | Phase 2 | withdrawn | Dec 18, 2013 | Centre Leon Berard | Industry decline to supply study drug | Drug supply |
| NCT00582400 | A Phase II Protocol of Arsenic Trioxide (Trisenox) in Subjects With Advanced Primary… | Phase 2 | terminated | Dec 28, 2007 | The University of Texas Medical Branch, Galveston | recruiting or enrolling participants has halted prematurely and will not resume; participants are… | Enrollment / accrual |
| NCT00532441 | Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract… | Phase 2 | terminated | Sep 20, 2007 | Gabi Chiorean, MD | Terminated due to funding issues. | Funding |
| NCT01161498 | Study of Safety and Efficacy of Talimogene Laherparepvec With Cisplatin and Radiotherapy… | Phase 3 | terminated | Jul 13, 2010 | BioVex Limited | The changing aetiology of squamous cell carcinoma of the head and neck (SCCHN). | Other (stated, no rule matched) |
| NCT00812266 | Topotecan and Cisplatin Versus Etoposide and Carboplatin in 1st Line Treatment of… | Phase 3 | terminated | Dec 22, 2008 | Danish Oncological Lung Cancer Group | Slow accrual | Enrollment / accrual |
| NCT01762033 | A Phase 2 Study of ASONEP™ to Treat Unresectable and Refractory Renal Cell Carcinoma | Phase 2 | terminated | Jan 7, 2013 | Lpath, Inc. | not stated | Not stated |
| NCT01532453 | Prevention of UV-induced Carcinogenic Skin Alterations in Immunosuppressed Solid Organ… | Phase 3 | terminated | Feb 14, 2012 | Spirig Pharma Ltd. | For futility reasons and potential "loss of chance" for MD 3511356 group | Efficacy / futility |
| NCT00299390 | Safety and Efficacy Study of a New Chemotherapy Agent to Treat Small Cell Lung Cancer | Phase 2 | terminated | Mar 6, 2006 | Bayer | Since only 1 of the first 10 subjects responded to the study treatment, it was decided to stop the… | Efficacy / futility |
| NCT00746655 | SBRT + TACE for Primary Hepatocellular Carcinoma | N/A | withdrawn | Sep 4, 2008 | University of Pittsburgh | Unable to recruit | Enrollment / accrual |
| NCT00272181 | Study of Proxinium for Treating Patients With Squamous Cell Head and Neck Cancer | Phase 2 | terminated | Jan 4, 2006 | Sesen Bio, Inc. | Slow accrual in North America | Enrollment / accrual |
| NCT00412776 | Study of Proxinium Plus Best Supportive Care Versus Best Supportive Care for Patients… | Phase 2 / Phase 3 | terminated | Dec 18, 2006 | Sesen Bio, Inc. | Corporate reasons unrelated to safety and efficacy | Safety / toxicity |
| NCT01771003 | Remote Ischemia Pre-Conditioning in Patients Undergoing Partial Nephrectomy | N/A | terminated | Jan 18, 2013 | University Health Network, Toronto | not stated | Not stated |
| NCT00480935 | A Study of Neoadjuvant Sutent for Patients With Renal Cell Carcinoma | Phase 2 | terminated | May 31, 2007 | University Health Network, Toronto | poor recruitment | Enrollment / accrual |
| NCT00669136 | Immunization With AFP + GM CSF Plasmid Prime and AFP Adenoviral Vector Boost in Patients… | Phase 1 | terminated | Apr 29, 2008 | Lisa H. Butterfield, Ph.D. | Poor accrual and limited target patient population for future accrual. Did not complete the Phase 1… | Enrollment / accrual |
| NCT00913913 | Bevacizumab, Autologous Tumor/DC Vaccine, IL-2 and IFNα-2b in Metastatic Renal Cell… | Phase 2 | terminated | Jun 4, 2009 | Dartmouth-Hitchcock Medical Center | low accrual not allowing site to meeting statistical endpoints | Enrollment / accrual |
| NCT01391039 | Diagnostic Study of Early Breast Cancer Using Ultrasound | N/A | terminated | Jul 11, 2011 | Sunnybrook Health Sciences Centre | Low recruitment | Enrollment / accrual |
| NCT02304445 | Chemoembolization With or Without Stereotactic Body Radiosurgery for Liver Cancer(TACE-SBRT) | N/A | withdrawn | Dec 2, 2014 | Juan Sanabria, MD | Necessary equipment could not be obtained. | Other (stated, no rule matched) |
| NCT01977586 | Functional Imaging in the Assessment of mRCC Response to Sunitinib | N/A | withdrawn | Nov 6, 2013 | Imperial College Healthcare NHS Trust | Difficulty in recruiting suitable patients at centre | Enrollment / accrual |
| NCT01159327 | Study of Sorafenib Maintenance in Patients With ED-SCLC After Response to Induction… | Phase 2 | terminated | Jul 9, 2010 | National Cancer Center, Korea | low enrolling participants | Enrollment / accrual |
| NCT02024685 | Treatment Decision Analysis Model for Prostate Cancer: A Randomized Trial | N/A | terminated | Dec 31, 2013 | Case Comprehensive Cancer Center | Funding unavailable | Funding |
| NCT01521780 | Characterization of Baseline Biomarker Variability in Participants With Hepatocellular… | Phase 1 | terminated | Jan 31, 2012 | Merck Sharp & Dohme LLC | not stated | Not stated |
| NCT02536495 | Selinexor and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell… | Phase 1 / Phase 2 | withdrawn | Sep 1, 2015 | Erin Bertino | PI decision due to funding support | Funding |
| NCT01911273 | A Study To Evaluate The Efficacy And Safety of The Investigational Drug PF-03446962 (A… | Phase 2 | terminated | Jul 30, 2013 | Pfizer | See termination reason in detailed description. | Other (stated, no rule matched) |
| NCT01856322 | Surgery Plus Sulindac or Surgery Alone for Advanced Colorectal Cancer | Phase 2 | terminated | May 17, 2013 | National Cancer Institute (NCI) | The trial was prematurely closed due to lack of accrual. | Enrollment / accrual |
| NCT02042885 | A Clinical Trial to Determine the Most Suitable Dose of OPB-111001 in Patients With… | Phase 1 / Phase 2 | terminated | Jan 23, 2014 | Otsuka Novel Products GmbH | not stated | Not stated |
| NCT01108705 | Comparison of Brivanib and Best Supportive Care (BSC) With Placebo and BSC for Treatment…(BRISK-APS) | Phase 3 | terminated | Apr 22, 2010 | Bristol-Myers Squibb | not stated | Not stated |
| NCT00227773 | Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors | Phase 2 | withdrawn | Sep 28, 2005 | Eastern Cooperative Oncology Group | not stated | Not stated |
| NCT00755157 | Metronomic Docetaxel and Bevacizumab in Patients With Small Cell Lung Cancer | Phase 2 | withdrawn | Sep 18, 2008 | University Hospital of Crete | not stated | Not stated |
| NCT01342627 | Sorafenib in Elderly Patients With Metastatic Renal Cell Carcinoma(SERCC) | Phase 2 | terminated | Apr 27, 2011 | Centro di Riferimento Oncologico - Aviano | low enrollment rate | Enrollment / accrual |
| NCT00798057 | Proton Radiation Therapy for Pituitary Adenoma(PI01) | — | terminated | Nov 25, 2008 | University of Florida | Due to slow enrollment and feasibility issues. | Enrollment / accrual |
| NCT01239355 | MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous… | Phase 2 | terminated | Nov 11, 2010 | National Cancer Institute (NCI) | Early termination for discouraging results | Other (stated, no rule matched) |
| NCT01963715 | A Phase 1 Study of IMGN289 in Adult Patients With EGFR-positive Solid Tumors | Phase 1 | terminated | Oct 16, 2013 | ImmunoGen, Inc. | not stated | Not stated |
| NCT01968629 | 24hr Imaging Of HCC After EOVIST | Early Phase 1 | withdrawn | Oct 24, 2013 | Massachusetts General Hospital | No eligible subject enrolled | Enrollment / accrual |
| NCT01100242 | Velcade and Sorafenib in Unresected or Metastatic Renal Cell Carcinoma | Phase 2 | terminated | Apr 8, 2010 | New Mexico Cancer Research Alliance | Low accrual | Enrollment / accrual |
| NCT00598091 | A Phase I/Expansion Study of Dasatinib(Gem/Dsat) | Phase 1 | terminated | Jan 18, 2008 | Duke University | Low accrual, unable to meet endpoint in timely manner | Enrollment / accrual |
| NCT01238133 | Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097, Paclitaxel, and Carboplatin… | Phase 1 | terminated | Nov 10, 2010 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01586182 | Stereotactic Boost for Oropharyngeal Squamous Cell Carcinoma | Phase 1 / Phase 2 | withdrawn | Apr 26, 2012 | Dana-Farber Cancer Institute | Local IRB closed the study due to poor accural. | Other (stated, no rule matched) |
| NCT01949740 | Patient Preferences in Making Treatment Decisions in Patients With Stage I-IVA… | — | terminated | Sep 24, 2013 | University of Chicago | Poor accrual | Enrollment / accrual |
| NCT01368003 | STA-9090 in Castration-Resistant Prostate Cancer With Assessment of Androgen Receptor… | Phase 2 | withdrawn | Jun 7, 2011 | Toni Choueiri, MD | Loss of funding. | Funding |
| NCT01348503 | Lenalidomide in Combination With a Fixed Dose of Sorafenib for the Treatment of… | Phase 1 | terminated | May 5, 2011 | Indiana University | Treatment was ineffective | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Apr 7, 2016source: clinicaltrials